Akebia Therapeutics, Inc.
AKBAAkebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease. The company's lead product, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor intended to treat anemia associated with chronic kidney disease. Akebia aims to address unmet medical needs in renal conditions through innovative treatments.
Company News
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.
Akebia Therapeutics' Chief Commercial Officer Nik Grund will participate in a Fireside Chat at the 4th Annual Kidney Virtual Conference on July 14, 2025, discussing the company's kidney disease research and developments.
Averoa, a biopharmaceutical company, has received European marketing authorization for its oral therapy XOANACYL, which addresses iron deficiency and hyperphosphatemia in chronic kidney disease patients.
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that it will present three posters at the European Renal Association Congress 2025.
